News | News By Subject | News by Disease News By Date | Search News

Leukemia [Acute myelogenous leukemia (AML)] News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Seattle Genetics (SGEN) Takes Another Hit as the FDA Slaps Hold on IND for Vadastuximab Talirine     6/23/2017
GlycoMimetics (GLYC) Stock Takes Off on Positive Phase II Leukemia Data, Breakthrough Tag     5/18/2017
4 Fatal Deaths in Seattle Genetics (SGEN)' Early-Stage Trials of AML Drug     12/30/2016
New York’s Cellectis (ALCLS) Looks to 2017 for Clinical Trials of AML Treatment     12/16/2016
FDA Places Clinical Hold on AML Drug Co-Developed by Johnson & Johnson (JNJ) and Genmab A/S (GEN.CO)     9/20/2016
Another Celgene (CELG) Bet Pays Off as Agios (AGIO) Eyes Early Approval of Leukemia Drug     9/8/2016
FDA Berates Celator Pharma (CPXX) for Pushing Unapproved Leukemia Drug to Doctors     9/8/2016
MEI Pharma (MSHL)'s Pracinostat Called a Breakthrough By the FDA     8/1/2016
Ultragenyx (RARE) Rising on Phase III Acute Myeloid Leukemia Data     7/15/2016
Celator Pharma (CPXX) Jumps on Breakthrough Therapy Win for Lead Cancer Drug     5/19/2016
3 Biotechs Getting Another Shot After Failed Trials     4/7/2016
Celator Pharma (CPXX) Stock Jumps 400% Premarket as AML Drug Wows in Phase III Study     3/16/2016
Akinion Halts Further Development of AKN-028 Due to Safety Concerns     3/4/2016
Forty Seven Launches with Half of $75 Million Series A Backed by Google (GOOG) and 100+ Patents     2/26/2016
Novartis AG (NVS)'s Leukemia Drug Gets Breakthrough Designation, Same Week as AstraZeneca PLC (AZN) and Roche (RHHBY) Drugs     2/22/2016

News from Around the Web
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines     6/19/2017
Less Is More With Acute Myeloid Leukemia Drug, Erasmus University Medical Center Study     3/17/2011
Mutations in Single Gene Predict Poor Outcomes in Adult Leukemia; Discovery May Guide Treatment for Acute Myeloid Leukemia, Washington University Study     11/11/2010
Protein That Predicts Prognosis Of Leukemia Patients May Also Be A Therapeutic Target, Whitehead Institute and Children's Hospital Boston Reveals     7/12/2010
Umbilical Cord Best Treatment for Childhood Leukaemia     6/8/2007
Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down     3/1/2007
Researchers Develop New Strategy For The Treatment Of CML     1/18/2007
Role For Proteomics In Identifying Hematologic Malignancies     1/11/2007
Study Identifies Molecular Process Underlying Leukemia     8/22/2006
Cytoplasmic Location Of Shuttling Protein Often Seen With AML     1/20/2005
Perpetual AML Can Arise From Rare Leukemic Stem Cell     6/1/2004
Gene Expression Profiling Yields Prognostic Information For AML Patients     4/14/2004

Press Releases
Syros Pharma Publishes Foundational Data Supporting Ongoing Phase II Clinical Trial Of SY-1425 For Genomically Defined AML And MDS Patients     7/21/2017
Novartis AG (NVS) Receives Positive CHMP Opinion For Rydapt (Midostaurin) For Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) And Three Types Of Advanced Systemic Mastocytosis (SM)     7/21/2017
U.S. FDA Grants Orphan-Drug Designation To Astellas (ALPMY) For Development Of FLT3 Inhibitor Gilteritinib In Acute Myeloid Leukemia     7/20/2017
Imago Biosciences Doses First Patients In The Phase IIa Portion Of The Study Of IMG-7289 In Acute Myeloid Leukemia And Myelodysplastic Syndrome     7/19/2017
Actinium (ATNM.OB) To Host Webinar Focused On Actimab-A And Recent Developments Related To CD33 Targeted AML Therapies On July 13, 2017 At 8:00 Am ET     7/13/2017
TrovaGene (TROV) Engages Leading CRO In AML To Conduct Phase Ib/II Trial Of PCM-075     7/6/2017
Actinium (ATNM.OB) To Host Webinar Focused On Actimab-A And Recent Developments Related To CD33 Targeted AML Therapies On July 13, 2017 At 8:00 Am ET     7/6/2017
Immune Pharma's Oncology Subsidiary, Cytovia, Inc. (MAXM), Announces Additional Clinical Trial Results On The Efficacy Of Ceplene In Combination With Low-Dose IL-2 In Patients With Acute Myeloid Leukemia, Recently Published In Leukemia, A Leading Hematology Journal     7/5/2017
TrovaGene (TROV) Announces Submission Of Investigational New Drug Application To Initiate Phase Ib/II Clinical Trial Of PCM-075 For Acute Myeloid Leukemia     6/27/2017
The New England Journal of Medicine Publishes Full Analysis Of Rydapt (Midostaurin) Phase III RATIFY Trial In Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)     6/26/2017
Onconova (ONTX) Presents Rigosertib Data At The 22nd Congress Of The European Hematology Association In Madrid     6/26/2017
The Lancet Oncology Publishes Anti-Leukemic Activity And Safety Data For Gilteritinib In Relapsed/Refractory Acute Myeloid Leukemia     6/23/2017
Positive Phase Ib Data For NewLink Genetics (NLNK)’ IDO Pathway Inhibitor, Indoximod, In Combination With Chemotherapy For Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Presented At The European Hematology Association Congress In Madrid, Spain     6/23/2017
Tolero Pharmaceuticals To Expand Enrollment Of Phase II Study Of Alvocidib In MCL-1-Dependent AML Into Europe     6/21/2017
Actinium (ATNM.OB) To Host Webinar On June 12th To Update On Pivotal Phase III SIERRA Clinical Trial For Iomab-B     6/12/2017